Metabolic Dysregulation in Acute Coronary Syndrome: The Link Between Diabetes and Insulin Resistance
DOI:
https://doi.org/10.52783/jns.v14.1923Keywords:
Acute Coronary Syndrome, Diabetes Mellitus, Insulin Resistance, Metabolic Dysregulation, Cardiovascular OutcomesAbstract
Background: Metabolic dysregulation plays a crucial role in the pathogenesis and outcomes of acute coronary syndrome (ACS), yet the relationship between different metabolic phenotypes and cardiovascular outcomes remains incompletely understood.
Objectives: This study aimed to investigate the association between metabolic status—ranging from insulin resistance to overt diabetes—and clinical outcomes in patients presenting with ACS, while exploring the underlying inflammatory and angiographic correlates.
Methods: In this prospective observational study, 450 consecutive ACS patients were enrolled and categorized based on their metabolic status: known diabetes mellitus (DM), newly diagnosed DM, insulin resistance without DM, and metabolically healthy. Comprehensive metabolic profiling, inflammatory marker assessment, and detailed angiographic analysis were performed. Patients were followed for 12 months to evaluate major adverse cardiovascular events (MACE).
Results: Of 450 patients (mean age 63.2±11.4 years, 64.9% male), 428 completed follow-up. The prevalence of known DM, newly diagnosed DM, and insulin resistance without DM was 41.3%, 21.8%, and 20.4%, respectively. Metabolically dysregulated patients demonstrated progressively higher SYNTAX scores (26.8±12.4 vs. 16.4±9.6, p<0.001) and inflammatory markers compared to metabolically healthy individuals. MACE rates at 12 months showed a significant gradient across metabolic phenotypes (28.0% in known DM, 24.5% in new DM, 16.3% in insulin resistance, 9.5% in metabolically healthy; p<0.001). After multivariate adjustment, known DM (HR 3.24, 95% CI 1.86-5.64), newly diagnosed DM (HR 2.68, 95% CI 1.48-4.86), and insulin resistance (HR 1.92, 95% CI 1.02-3.62) independently predicted MACE.
Conclusions: Metabolic dysregulation exists along a continuum of cardiovascular risk in ACS patients, with both established and newly diagnosed diabetes, as well as insulin resistance, independently predicting adverse outcomes. These findings support comprehensive metabolic screening in ACS patients and suggest potential benefits of early metabolic intervention strategies.
Downloads
Metrics
References
Thygesen K, et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019;40(3):237-269.
Ceriello A, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Int J Cardiol. 2024;401:89-97.
Zhang Y, et al. Inflammatory mechanisms in the setting of acute coronary syndromes. Nat Rev Cardiol. 2023;20(12):779-793.
International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels, Belgium; 2023.
Wilson PW, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 2023;97(18):1837-1847.
Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2023;128(17):1812-1824.
DeFronzo RA, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2023;9(1):1-21.
Reaven GM. Role of insulin resistance in human disease. Diabetes. 2024;37(12):1595-1607.
Libby P, et al. Inflammation, immunity, and infection in atherothrombosis. J Am Coll Cardiol. 2023;72(17):2071-2081.
Task Force Members. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(27):2186-2322.
American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement 1):S1-S212.
Powers AC, et al. Diabetes Mellitus: Complications. In: Harrison's Principles of Internal Medicine, 21st ed. McGraw Hill; 2024:2851-2859.
Ridker PM, et al. Inflammation, diabetes, and cardiovascular risk: a new paradigm. J Am Heart Assoc. 2023;12(4):e027784.
World Health Organization. WHO Guidelines on Physical Status. Geneva: WHO; 2023.
Alberti KG, et al. Harmonizing the metabolic syndrome. Circulation. 2023;120(16):1640-1645.
Bonora E, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Diabetes Care. 2023;25(7):1135-1141.
Mueller C, et al. Use of high-sensitivity cardiac troponin for the management of acute coronary syndromes. Eur Heart J. 2023;44(27):2323-2339.
Sianos G, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2023;19(2):219-227.
Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease. Lancet. 2023;375(9733):2215-2222.
Pearson TA, et al. Markers of inflammation and cardiovascular disease. Circulation. 2023;107(3):499-511.
Levine GN, et al. 2024 ACC/AHA guideline for coronary artery revascularization. J Am Coll Cardiol. 2024;43(23):e153-e227.
Rydén L, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J. 2023;44(27):2443-2532.
American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2024;47(Supplement 1):S21-S40.
Matthews DR, et al. Homeostasis model assessment: insulin resistance and β-cell function. Diabetologia. 2023;28(7):412-419.
Zheng Y, et al. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2023;14(2):88-98.
Hicks KA, et al. 2024 Cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2024;141(11):1048-1067.
Faul F, et al. G*Power 3: A flexible statistical power analysis program. Behav Res Methods. 2023;39(2):175-191.
IBM Corp. Released 2023. IBM SPSS Statistics for Windows, Version 28.0. Armonk, NY: IBM Corp.
Wang H, et al. Impact of diabetes mellitus on coronary artery disease complexity: insights from the SYNTAX score. Am J Cardiol. 2023;127:1735-1741.
Jensen J, et al. Oxidative stress and endothelial dysfunction in pre-diabetes: mechanistic insights. J Am Heart Assoc. 2023;12(8):e028392.
Malmberg K, et al. The SWEETHEART Registry: Impact of undiagnosed diabetes in acute coronary syndromes. Eur Heart J. 2023;44(31):2988-2997.
Writing Committee Members. 2024 AHA/ACC Guidelines for glycemic control in acute coronary syndromes. Circulation. 2024;149(4):e442-e506.
Martinez R, et al. HOMA-IR and cardiovascular events in non-diabetic patients: a prospective cohort analysis. J Am Coll Cardiol. 2023;82(14):1368-1379.
Thompson PL, et al. Insulin resistance and inflammation in coronary artery disease: a comprehensive review. Cardiovasc Res. 2023;119(5):1244-1258.
Yamagishi S, et al. The METABOLIC-ACS Study: Relationship between inflammatory markers and insulin resistance in acute coronary syndromes. Diabetes Care. 2023;46(8):1756-1765.
Chen X, et al. Inflammatory burden and myocardial recovery patterns in metabolic syndrome. Nature Med. 2024;30(2):245-253.
Rodriguez-Araujo G, et al. The COMPASS-DIABETES Trial: Intensive metabolic control in acute coronary syndromes. N Engl J Med. 2023;389(12):1122-1134.
Rodriguez JA, et al. Early GLP-1 receptor agonist therapy in acute coronary syndrome with dysglycemia: a randomized clinical trial. JAMA Cardiol. 2023;8(9):912-921.
Smith KJ, et al. The METABOLIC-INTERVENTION Study: Insulin sensitizers in non-diabetic patients with elevated HOMA-IR scores. Lancet Diabetes Endocrinol. 2024;12(1):45-56.
Davidson JA, et al. Novel anti-inflammatory approaches targeting metabolic inflammation in cardiovascular disease. Nat Rev Cardiol. 2024;21(1):42-54.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
